AR011410A1 - Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab - Google Patents

Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab

Info

Publication number
AR011410A1
AR011410A1 ARP980100152A ARP980100152A AR011410A1 AR 011410 A1 AR011410 A1 AR 011410A1 AR P980100152 A ARP980100152 A AR P980100152A AR P980100152 A ARP980100152 A AR P980100152A AR 011410 A1 AR011410 A1 AR 011410A1
Authority
AR
Argentina
Prior art keywords
formulation
gonadotrophins
liquid
liquid formulation
preparing
Prior art date
Application number
ARP980100152A
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR011410A1 publication Critical patent/AR011410A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion líquida que contiene gonadotrofinas que comprende una gonadotrofina y cantidades estabilizadoras de un ácido policarboxílico o de unasal del mismo y un compuesto tioéter. Un método para preparar una formulacion líquida degona dotrofinas. Las proteínas particulares (p. ej. LH, YSH, FSH oHCG) se mezclan con los estabilizantes determinados adicionándolas en solucion acuosa. Los preparados contienen una cantidad suficiente de un ácidopolicarboxílico o una sal delmismo, pref erentemente citrato de sodio, y una cantidad suficiente de un compuesto tioéter, preferentemente metionina, paraestabilizar la proteína. Los preparados incluyen preferentemente, también, un disacárido no reductor como la sucrosa,y un surfact ante no ionico.Un cartucho que contiene una formulacion líquida estéril que contiene gonadotrofinas. Un dispositivo para administrar la formulacion que comprendea este cartucho. Utilizacion de una gonadotrofina para laelaboracion de un medicamento líquido inyectable directamente para el tratamiento de lainfertilidad.
ARP980100152A 1997-01-15 1998-01-14 Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab AR011410A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15

Publications (1)

Publication Number Publication Date
AR011410A1 true AR011410A1 (es) 2000-08-16

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100152A AR011410A1 (es) 1997-01-15 1998-01-14 Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab

Country Status (30)

Country Link
US (1) US5929028A (es)
EP (2) EP1285665A1 (es)
JP (1) JP4353549B2 (es)
KR (1) KR100498531B1 (es)
CN (1) CN1165341C (es)
AR (1) AR011410A1 (es)
AT (1) ATE237348T1 (es)
AU (1) AU736339B2 (es)
BR (1) BR9800323B1 (es)
CA (1) CA2226803A1 (es)
CZ (1) CZ297419B6 (es)
DE (2) DE69813322T2 (es)
DK (1) DK0853945T3 (es)
ES (1) ES2196474T3 (es)
FR (1) FR10C0024I2 (es)
HK (1) HK1010150A1 (es)
HU (1) HU227154B1 (es)
ID (1) ID19499A (es)
IL (1) IL122732A0 (es)
LU (1) LU91655I2 (es)
MX (1) MX9800438A (es)
NO (3) NO322509B1 (es)
NZ (1) NZ329572A (es)
PL (1) PL190103B1 (es)
PT (1) PT853945E (es)
RU (1) RU2203086C2 (es)
SA (1) SA98181124B1 (es)
TR (1) TR199800062A2 (es)
TW (1) TW518235B (es)
ZA (1) ZA9883B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
BR9912243A (pt) * 1998-07-23 2001-10-16 Lilly Co Eli Formulações de fsh e variantes de fsh, produtos e processos
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CZ200260A3 (cs) * 1999-07-12 2002-04-17 Grandis Biotech Gmbh Formulace růstového hormonu
ATE356138T1 (de) * 2000-02-22 2007-03-15 Applied Research Systems Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (en) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Image forming method
US10105417B2 (en) 2003-03-04 2018-10-23 Aspenbio Pharma, Inc. Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone
AR043972A1 (es) 2003-04-02 2005-08-17 Ares Trading Sa Formulaciones farmaceuticas de fsh y lh
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
PT1638595E (pt) 2003-06-20 2013-04-26 Ares Trading Sa Fsh liofilizada / formulações de hl
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2008038817A1 (en) * 2006-09-25 2008-04-03 National University Corporation Tokyo University Of Agriculture And Technology Ultrasonic operation device and microtube inside system
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
AU2008267138B9 (en) 2007-06-28 2014-06-05 Theramex HQ UK Limited FSH producing cell clone
MX2010004639A (es) * 2007-11-01 2010-08-04 Merck Serono Sa Formulaciones liquidas de hormona luteinizante (lh).
ES2372470T3 (es) * 2008-02-08 2012-01-20 Biogenerix Ag Formulación líquida de fsh.
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
CA2742659C (en) 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
MX2015004940A (es) 2012-10-18 2015-12-09 Neuralight Hd Llc Tratamiento de depresion y ptsd.
EP2922867B1 (en) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3068374A1 (en) 2013-11-12 2016-09-21 Cadila Healthcare Limited Formulation for gonadotropins
NZ731143A (en) * 2014-10-21 2021-07-30 Hexima Ltd A method of treatment
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
BR112019004929A2 (pt) 2016-09-13 2019-06-04 Allergan Inc composições de toxina clostridial não proteíca
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3969026A1 (en) 2019-05-16 2022-03-23 Ceva Santé Animale Compositions and methods for increasing reproduction performance in non human mammals using recombinant luteinizing hormone
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN117783545A (zh) * 2023-12-28 2024-03-29 深圳市新产业生物医学工程股份有限公司 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
CA2636421C (en) * 1992-04-30 2010-06-29 Millennium Pharmaceuticals, Inc. A method of platelet and whole blood storage
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen

Also Published As

Publication number Publication date
DE69813322T2 (de) 2004-02-19
HU227154B1 (en) 2010-08-30
EP1285665A1 (en) 2003-02-26
PL324279A1 (en) 1998-07-20
MX9800438A (es) 1998-11-30
JPH10203997A (ja) 1998-08-04
FR10C0024I1 (es) 2010-05-21
CZ297419B6 (cs) 2006-12-13
RU2203086C2 (ru) 2003-04-27
KR19980070493A (ko) 1998-10-26
HU9800056D0 (en) 1998-03-02
JP4353549B2 (ja) 2009-10-28
HUP9800056A3 (en) 2001-01-29
BR9800323A (pt) 1999-06-29
CA2226803A1 (en) 1998-07-15
KR100498531B1 (ko) 2005-09-30
HK1010150A1 (en) 1999-06-17
NO322509B1 (no) 2006-10-16
FR10C0024I2 (fr) 2011-04-01
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
NO2021001I1 (no) 2021-01-12
CN1191139A (zh) 1998-08-26
CN1165341C (zh) 2004-09-08
CZ13598A3 (cs) 1998-08-12
PL190103B1 (pl) 2005-10-31
NO980177L (no) 1998-07-16
EP0853945B1 (en) 2003-04-16
DK0853945T3 (da) 2003-08-04
TR199800062A2 (xx) 1998-08-21
TW518235B (en) 2003-01-21
NZ329572A (en) 1999-05-28
ID19499A (id) 1998-07-16
NO2010013I2 (no) 2015-05-18
DE69813322D1 (de) 2003-05-22
HUP9800056A2 (hu) 1998-08-28
DE122010000011I1 (de) 2010-07-08
AU5205998A (en) 1998-07-23
LU91655I2 (fr) 2010-04-26
NO980177D0 (no) 1998-01-14
ZA9883B (en) 1998-07-08
IL122732A0 (en) 1998-08-16
SA98181124B1 (ar) 2006-07-10
NO2010013I1 (no) 2010-06-07
AU736339B2 (en) 2001-07-26
ES2196474T3 (es) 2003-12-16
PT853945E (pt) 2003-08-29
US5929028A (en) 1999-07-27
EP0853945A1 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
AR011410A1 (es) Una formulacion liquida que contiene gonadotrofinas, un metodo para preparar una composicion liquida de gonadotrofinas, un cartucho que contiene una formulacion liquida esteril, un dispositivo para administrar la formulacion y utilizacion de la formulacion que contiene la gonadotrofinas para la elab
DE69232847T2 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
JP5364374B2 (ja) ｈＦＳＨ水性製剤
RU98100930A (ru) Жидкие композиции, содержащие гонадотропин
PT2249869E (pt) Formulação líquida da fsh
ES2097783T3 (es) Nanomatrices proteicas y procedimiento de produccion.
ES2057731T3 (es) Preparaciones que contienen gonadotropinas estabilizadas.
EP2533800B1 (en) Liquid formulation of follicle stimulating hormone
SE7600284L (sv) Terapeutisk insulinberedning.
KR940703689A (ko) 성장호르몬과 아스파라진으로 이루어지는 안정화된 약학제제(a stabil-ized pharmaceutical formulation comprising growth gormone and asparagine)
KR20100088147A (ko) Ｌｈ 액체 제형
KR20080106636A (ko) 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
AR040526A1 (es) Formulaciuones de hgh en alta concentracion que contienen fenol
KR970706841A (ko) 성장호르몬 및 루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and leucine)
KR970706839A (ko) 성장호르몬 및 이소루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and isoleucine)
ES2358330T5 (es) Formulaciones farmacéuticas líquidas de FSH y LH junto con un tensioactivo no iónico
ATE137971T1 (de) Verfahren zum herstellen von arzneizusammensetzungen, die vecuroniumbromid enthalten
RU2599031C1 (ru) Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты)

Legal Events

Date Code Title Description
FG Grant, registration